|Agency:||Department of the Navy|
|Type of Government:||Federal|
|Posted Date:||Oct 11, 2017|
|Due Date:||Oct 27, 2017|
|Bid Source:||Please Login to View Page|
|Contact information:||Please Login to View Page|
|Bid Documents:||Please Login to View Page|
Solicitation Number :
Notice Type :
Added: Oct 11, 2017 4:06 pmThe U.S. Naval Medical Research Unit No. 6 (NAMRU-6) in Peru is evaluating the development of an effective prophylactic to control enterotoxigenic E. coli (ETEC) caused diarrhea. Individual vaccine candidates are being evaluated in an established Aotus nancymaae preclinical model of diarrhea. Continued used of the A. nancymaae monkey in these studies is essential for comparative analysis across studies and maintenance of an established model of disease.
Background: Non-human primate models of human diarrheal diseases caused by ETEC, Campylobacter and Shigella have been developed at NAMRU6 using A. nancymaae. These models represent a unique asset to test the efficacy of vaccines targeting enteric diseases. To date, candidate vaccines against individual strains of ETEC have been tested in the Aotus non-human primate model. We will now test the protective efficacy of a human anti-ETEC antibody product using the Aotus nancymaae model for diarrhea caused by a CFA/I expressing ETEC strain.
For the completion of these studies, we shall require 39 Aotus Nancymaae (Owl Monkeys) non-human primates. All animals shall be of good health. For the scientific consistency and comparative analysis, the delivered Aotus Nancymaae animals must have an equal gender distribution (in so much as possible) and be at 12 months of age and weighing over >700 grams at the time of the initiation of the study.
This pre-solicitation is not a request for competitive proposals and no solicitation document exists for the requirement. Sources interested in responding to this notice are required to submit a capability statement that includes management and technical data and cost information, in sufficient detail and with convincing evidence that clearly demonstrates the capability to perform the required work. Capability statements shall not exceed 5 (8.5 x 11 inch) pages using a font size no smaller than 10-point. All capability statements received by the due date of this notice will be considered by the Government. A request for documentation or additional information or submissions that only ask questions will not be considered as an affirmative response. A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement or to proceed with a sole source contract.
Capability statements are due by 12:00 AM Local Time, October 27th, 2017. Capability statements shall be submitted by e-mail ONLY as a Microsoft Word or Adobe PDF attachment to the following address: Javier.email@example.com Please use subject line "N44852_AOTUS_39".
Contracting Office Address :
Unit 3230 Box 343
DPO AA 34031-0343
Lima, Non-U.S. 34031-0343
Place of Performance :
NAVALE MEDICAL RESEARCH UNIT 6
HOSPITAL NAVAL DEL PERU
AV VENEZUELA CUADRA 36 S/N
Primary Point of Contact. :
Javier B. Gil,
Secondary Point of Contact :
Genaro M Vasquez,